Pharmacies must pay $650.6 million to Ohio counties in opioid case

Pharmacies must pay 0.6 million to Ohio counties in opioid case


A customer views merchandise for sale at a Walgreens store in the Hollywood neighborhood of Los Angeles.

Christopher Lee | Bloomberg | Getty Images

Pharmacy operators CVS, Walmart and Walgreens must pay a combined $650.6 million to two Ohio counties to address the damage done by the opioid epidemic, a federal judge ruled on Wednesday.

The order by U.S. Judge Dan Polster in Cleveland comes after a jury last November concluded that the pharmacy chains helped create a public nuisance in Lake and Trumbull counties by over-supplying addictive pain pills, many of which found their way onto the black market. The pharmacies have said they would appeal that verdict.

Polster held a separate non-jury trial earlier this year to decide how much the companies had to pay.

“We are disappointed with this outcome,” Walgreens spokesman Fraser Engleman said in a statement. “The facts and the law did not support the jury verdict last fall, and they do not support the court’s decision now.”

CVS and Walmart did not immediately respond to requests for comment.

Polster said the sum must be paid over 15 years, with the amount for the first two years, or $86.7 million, to be paid into a fund immediately. The judge also ordered the companies to implement new procedures to combat illegal diversion of opioid drugs.

The U.S. opioid epidemic has caused more than 500,000 overdose deaths over two decades, according to government data. More than 3,300 opioid lawsuits have been filed nationally against drugmakers, distributors and pharmacy chains.

The litigation has resulted in several nationwide settlements, including a $26 billion deal with Johnson & Johnson and the three leading distributors, a $2.37 billion settlement with AbbVie Inc and a $4.25 billion settlement with Teva Pharmaceutical Industries Ltd.

Pharmacies have yet to reach a nationwide settlement.



Source

Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Health

Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise

Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]

Read More
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market 
Health

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market 

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and […]

Read More
Private equity reduces patient care while enriching investors, Senate report finds
Health

Private equity reduces patient care while enriching investors, Senate report finds

A year-long bipartisan Congressional investigation into two private equity-backed U.S. hospital systems found that patient care deteriorated at both operations as their private equity owners reaped significant payouts on their investments in the systems. The findings reinforced academic research showing how private equity healthcare investments harm patients while enriching investors.  The investigation was helmed by two senators […]

Read More